-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

616.O1.6 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors in AML

Symposia: Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, Research, Clinical trials, AML, Lymphoid Leukemias, ALL, Adult, Combination therapy, Drug development, Clinical Research, Chemotherapy, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events, Non-Biological therapies, Myeloid Malignancies, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024: 2:00 PM-3:30 PM
Ballroom 20CD (San Diego Convention Center)
Moderators:
Rupa Narayan, MD, Massachusetts General Hospital and Sylvain Garciaz, MD, Institut Paoli-Calmettes
Disclosures:
Narayan: Novartis: Other: Research funding to the institution; Sanofi: Other: Spouse employment.

This session is dedicated to menin inhibitors used in monotherapy or in combination with standard treatments in AML (phase I/II).
2:00 PM

Ibrahim Aldoss, MD1, Ghayas C. Issa, MD2, James S. Blachly, MD3, Michael J. Thirman, MD4,5, Gabriel N Mannis, MD6, Martha L. Arellano, MD7, John F. DiPersio, MD, PhD8, Elie Traer, MD, PhD9, C. Michel Zwaan, Prof. Dr.10,11*, Neerav Shukla, MD12, Branko Cuglievan, MD13, Carolyn S. Grove, MBBS, FRACP, FRCPA, PhD14, Matthew Greenwood, MBBS, FRACP, FRCPA15, Christine M. McMahon, MD16, Alexander E. Perl, MD17, Richard M. Stone, MD18, Cristina Papayannidis, MD, PhD19, David S. Dickens, MD, FAAP20*, Maël Heiblig, MD, PhD21*, Andrius Žučenka, MD22,23, Pau Montesinos, PhD, MD24*, Ioannis Mantzaris, MD25, Tibor Kovacsovics, MD26*, Paul J. Shami, MD27, Li Yu, PhD28*, Rebecca G. Bagley, MA28*, Nicole McNeer, MD, PhD28* and Eytan M. Stein, MD12

1City of Hope National Medical Center, Duarte, CA
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3The Ohio State University, Columbus, OH
4The University of Chicago Medicine, Chicago, IL
5Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL
6Stanford University School of Medicine, Stanford, CA
7Emory University School of Medicine, Atlanta, GA
8Washington University School of Medicine, St. Louis, MO
9Knight Cancer Institute, Oregon Health & Science University, Portland, OR
10Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
11Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
12Memorial Sloan Kettering Cancer Center, New York, NY
13Division of Pediatrics, MD Anderson Cancer Center, Houston, TX
14Sir Charles Gairdner Hospital, Nedlands, Australia
15Royal North Shore Hospital, Sydney, NSW, Australia
16University of Colorado School of Medicine, Denver, CO
17Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA
18Dana-Farber Cancer Institute, Boston, MA
19Institute of Hematology and Medical Oncology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
20University of Iowa Stead Family Children's Hospital, Iowa City, IA
21Hematology, Centre Hospitalier Lyon Sud, Lyon, France
22Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
23Hematology and Oncology Department, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
24Hospital Universitari i Politècnic La Fe, Valencia, Spain
25Montefiore Einstein Comprehensive Cancer Center, Bronx, NY
26City of Hope Phoenix, Goodyear, AZ
27University of Utah Huntsman Cancer Institute, Salt Lake City, UT
28Syndax Pharmaceuticals, Inc., Waltham, MA

2:15 PM

Emma Searle, MD, PhD1*, Christian Recher, MD, PhD2*, Maher Abdul-Hay, MD3*, Sameem Abedin, MD4, Ibrahim Aldoss, MD5, Ana Alfonso Pierola, MD, PhD6*, Juan M. Alonso-Dominguez, MD, PhD7*, Patrice Chevallier, MD, PhD8, Carrye Cost, MD9*, Nikki Daskalakis, MD9*, Richard Dillon, MA10, Neil Dunavin, MD, MS11*, Jordi Esteve, MD, PhD12, Amir T. Fathi, MD13, Pasquale L. Fedele, MBBS, PhD, FRACP, FRCPA14*, Lucille Ferrante, MD, MS9, Stan Gaj, MSc15*, Christina Guttke, PhD9*, Emmanuel Gyan, MD, PhD16, Brett Hiebert, MS17*, Elias Jabbour, MD18, Hagop M. Kantarjian, MD18, Min Chul Kwon, PhD15, Anita J Kumar, MD, MSCE, PhD9, Teng Fong Ng, BSc, MBBS, MRCP, FRACP, FRCPA19*, Kathryn Packman, PhD20*, Ulrike Philippar, PhD21, Arnaud Pigneux, MD, PhD22*, Olga Salamero, MD23*, Madhu Sanga, PhD24*, Prathap Nagaraja Shastri, PhD9*, Richard M. Stone, MD25, Peter T. Tan, MBBS26, Trevor Tucker, BS9*, Paresh Vyas, FMedSci, DPhil, FRCPath27* and Sylvain Garciaz, MD28*

1The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom
2University Cancer Institute Toulouse Oncopole, Toulouse, France
3Blood and Marrow Transplantation and Cellular Therapy, Laura and Issac Perlmutter Cancer Center at NYU Langone Health, New York, NY
4Medical College of Wisconsin, Milwaukee, WI
5City of Hope National Medical Center, Duarte, CA
6Clínica Universidad de Navarra, Navarra, Spain
7Hospital Universitario Fundacion Jimenez Diaz - IISFJD-UAM, Madrid, Spain
8Nantes University Hospital, Nantes, France
9Janssen Research & Development, LLC, Spring House, PA
10Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom
11University of California San Francisco, San Francisco, CA
12Hematology Department, Hospital Clínic de Barcelona, Barcelona, Spain
13Massachusetts General Hospital, Harvard Medical School, Boston, MA
14Monash Health and School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
15Janssen Research & Development, LLC, Beerse, Belgium
16Centre Hospitalier Universitaire de Tours, Tours, France
17IQVIA, Winnipeg, MB, Canada
18MD Anderson Cancer Center, University of Texas, Houston, TX
19Gold Coast University Hospital and Griffith University, Queensland, Australia
20Janssen Research & Development, LLC, Cambridge, MA
21Janssen Research & Development, Beerse, Belgium
22Hopital Haut Leveque, Pessac, France
23University Hospital Vall d’Hebron, and Experimental Hematology, Vall d’Hebron Institute of Oncology, Barcelona, Spain
24Janssen Research & Development, LLC, Brisbane, CA
25Dana-Farber Cancer Institute, Boston, MA
26Royal Perth Hospital, Perth, Australia
27Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
28Aix-Marseille Université, Inserm, CNRS, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France

2:30 PM

Joshua F. Zeidner, MD1, Junichiro Yuda, MD, PhD2, Justin M. Watts, MD3, Mark J. Levis4, Harry P. Erba, MD, PhD5, Kentaro Fukushima, MD, PhD6*, Takahiro Shima, MD, PhD7, Neil D. Palmisiano, MD, MS8, Eunice S. Wang, MD9, Uma Borate, MD10, Joseph Brandwein, MD11, Cristina Papayannidis, MD, PhD12, Pau Montesinos, PhD, MD13*, Gina Keiffer, MD14, Yasushi Miyazaki, MD, PhD15, Naoko Hosono, MD, PhD16, Takayuki Ikezoe, MD, PhD17, Yoshiaki Ogawa, MD, PhD18*, Timothy S Pardee, MD, PhD19, Stephen Anthony Strickland, MD20, Koichi Onodera, MD21*, Shang-Ju Wu, MD, PhD22*, Melissa G Ooi, MB BCh, BAO, MRCP(I), FRCPath, PhD23*, Emmanuel Raffoux, MD24*, Susana Vives, MD25*, Alireza Eghtedar, MD26, Hongliang Cai, PhD27*, Curtis Allred, PhD28*, Bo Xu, PhD27*, Priya Robson27*, Akinobu Watanabe27*, Matthew Hitron, MD27*, Jatin Shah, MD27, Hagop M. Kantarjian, MD29 and Naval Daver, MD29

1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
2National Cancer Center Hospital East, Kashiwa, Japan
3Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL
4Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
5Duke University Cancer Institute, Durham, NC
6Osaka University Graduate School of Medicine, Suita, Japan
7Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan
8Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
9Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
10The Ohio State University, Columbus, OH
11Department of Medicine, University of Alberta, Edmonton, AB, Canada
12IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
13Hematology, Hospital Universitari I Politécnic La Fe and Programa Español de Tratamientos en Hematología (PETHEMA) Group, Valencia, Spain
14Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA
15Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan
16Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
17Fukushima Medical University, Fukushima, Japan
18Tokai University School of Medicine, Kanagawa, Japan
19Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC
20Sarah Cannon Research Institute, Nashville, TN
21Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan
22National Taiwan University Hospital, Taipei, Taiwan
23Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
24Hematology Department, Saint Louis Hospital, Paris, France
25Hematology Department, Institut Catala d'Oncologia - Hospital Germans Trias i Pujol, Badalona, Spain
26Colorado Blood Cancer Institute, Denver, CO
27Sumitomo Pharma America, Inc., Marlborough, MA
28Sumitomo Pharma America, Inc., Marlborough
29Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

2:45 PM

Amer M. Zeidan, MBBS, MHS1, Eunice S. Wang, MD2, Ghayas C. Issa, MD3, Harry Erba, MD, PhD4*, Jessica Altman, MD5, Suresh Kumar Balasubramanian, MD6,7, Stephen Anthony Strickland, MD8, Gail J. Roboz, MD9, Gary J. Schiller, MD10, Christine M. McMahon, MD11, Neil D. Palmisiano, MD, MS12, Yazan F. Madanat, MD13, Marcello Rotta, MD14*, Kalyan Nadiminti, MBBS15, Helen Wei, PhD16*, Marcie Riches, MD16*, Daniel Corum, PhD16*, Mollie Leoni, MD16*, Stephen Dale, MD16* and Amir T. Fathi, MD17

1Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT
2Roswell Park Comprehensive Cancer Center, Buffalo, NY
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Duke Cancer Institute, Durham, NC
5Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
6Department of Oncology, Karmanos Cancer Institute/ Wayne State University, Detroit, MI
7Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8SCRI at TriStar Centennial, Nashville, TN
9Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY
10David Geffen School of Medicine at UCLA, Los Angeles, CA
11Anschutz Medical Campus, Division of Hematology, University of Colorado School of Medicine, Aurora, CO
12Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
13The University of Texas Southwestern Medical Center, Dallas, TX
14Colorado Blood Cancer Institute, Denver, CO
15Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI
16Kura Oncology, Inc., San Diego, CA
17Massachusetts General Hospital, Harvard Medical School, Boston, MA

3:00 PM

Christian Recher, MD, PhD1*, Jenny O'Nions2*, Ibrahim Aldoss, MD3, Ana Alfonso Pierola, MD, PhD4*, Alicia Allred5*, Juan Manuel Alonso-Dominguez, MD, PhD6*, Laura Barreyro, PhD7, Pierre Bories, MD, PhD8*, Martin Curtis9*, Nikki Daskalakis, MD7*, Matteo Giovanni Della Porta, MD10*, Hartmut Döhner, MD11, Amber D’Souza, MD7*, James P. Dugan, MD12, Jordi Esteve Reyner, MD, PhD13*, Matthew Exum, MSN7*, Amir T. Fathi, MD14, Pasquale L. Fedele, MBBS, PhD, FRACP, FRCPA15*, Lucille Ferrante, MD, MS7, Stan Gaj, MSc16*, Sylvain Garciaz, MD17*, Ana Garrido, MD18*, Sara Garrido Paniagua, MD19*, Christina Guttke, PhD7*, Emmanuel Gyan, MD, PhD20*, Brett Hiebert, MS21*, Elias Jabbour, MD22, Madlen Jentzsch, MD23*, Hagop M. Kantarjian, MD24, Marina Konopleva25, Jan Krönke, MD26, Min Chul Kwon16*, Christina Loefgren, MD, PhD27, Oliver Lomas, BMBCh, MRCP, FRCPath, DPhil28*, Valentina Mancini, MD29*, Ioannis Mantzaris, MD30, Giovanni Martinelli, M.D.31, Daniel Morillo Giles, MD32*, Joseph Murphy, MD28*, Kathryn Packman, PhD33*, Cristina Papayannidis, MD, PhD34*, Ulrike Philippar, PhD35, Uwe Platzbecker, MD23, Sravanti Rangaraju, MBBS36, Christoph Röllig, MD, MSc37*, Olga Salamero, MD38*, Madhu Sanga, PhD39*, Tim Sauer, MD40, Emma Searle41*, Natalia Tovar42*, Trevor Tucker, BS7*, Nicolas Vallet, MD. PhD20*, Lachlin Vaughan, MBBS, PhD43*, Gala Vega, MD44*, Paresh Vyas, FMedSci, DPhil, FRCPath45* and Andrew Wei, MBBS, PhD46*

1University Cancer Institute Toulouse Oncopole, Toulouse, France
2University College London Hospital NHS Foundation Trust, London, United Kingdom
3City of Hope National Medical Center, Duarte, CA
4Clínica Universidad de Navarra, Navarra, Spain
5Janssen Research & Development, LLC, Titusville, NJ
6Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
7Janssen Research & Development, LLC, Spring House, PA
8hematologie, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
9Janssen Research & Development, LLC, Durham, NC
10IRCCS Humanitas Research Hospital and Humanitas University, Rozzano, Milan, Italy
11Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
12Malignant Hematology and Cellular Therapy Department, Novant Health Cancer Institute - Forsyth Medical Center, Winston, Salem, NC
13Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain
14Massachusetts General Hospital, Harvard Medical School, Boston, MA
15Monash Health and School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
16Janssen Research & Development, LLC, Beerse, Belgium
17Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France
18Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
19Experimental Hematology Unit, Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, University Autonoma of Barcelona (UAB), Barcelona, Spain
20Centre Hospitalier Universitaire de Tours, Tours, France
21IQVIA, Winnipeg, MB, Canada
22MD Anderson Cancer Center, University of Texas, Houston, TX
23Universitätsklinikum Leipzig, Leipzig, Germany
24Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
25Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY
26Charité - Universitätsmedizin Berlin, Berlin, Germany
27Janssen Global Services, LLC, Raritan, NJ
28Janssen Research & Development, LLC, High Wycombe, United Kingdom
29ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
30Albert Einstein College of Medicine, Bronx, NY
31IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
32START Madrid-FJD Early Phase Unit, Fundación Jiménez Díaz University Hospital, Madrid, Spain
33Janssen Research & Development, LLC, Cambridge, MA
34IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, Bologna, Italy
35Janssen Research & Development, Beerse, Belgium
36University of Alabama, Birmingham, AL
37Universitätsklinikum TU Dresden, Dresden, Germany
38Hematology Department, University Hospital Vall d’Hebron, Barcelona, Spain
39Janssen Research & Development, LLC, Brisbane, CA
40Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
41The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom
42Hospital Clínic de Barcelona, Barcelona, Spain
43Westmead Hospital, Sydney, Australia
44University Hospital Fundación Jiménez Díaz, Madrid, Spain
45Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
46Walter and Eliza Hall Institute of Medical Research and University of Melbourne, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Australia

3:15 PM

Ghayas C. Issa, MD1, Branko Cuglievan, MD2, Naval Daver, MD3, Courtney D. DiNardo, MD, MSc1, Aziz Farhat4*, Nicholas J. Short, MD1, David McCall, MD2, Allison Pike, RN1*, Sheila Tan, RN1*, Brianna Kammerer, BSN, MS, RN5*, Aimee Marshal1*, Musa Yilmaz, MD1*, Tapan M. Kadia, MD1, Naveen Pemmaraju, MD6, Maro Ohanian, DO1*, Hussein A. Abbas, MD, PhD1, Abhishek Maiti, MBBS7, Alexandre Bazinet, MD1*, Elias Jabbour, MD1, Koji Sasaki, MD1, Gautam Borthakur, MD8, Guillermo Montalban-Bravo, MD1, Nitin Jain, MD1, Yesid Alvarado Valero, MD1, Farhad Ravandi, MBBS9, Guillermo Garcia-Manero, MD1, Michael Andreeff, MD, PhD8 and Hagop M. Kantarjian, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Division of Pediatrics, MD Anderson Cancer Center, Houston, TX
3MD Anderson Cancer Center, Houston, TX
4The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, The University of Texas MD Anderson Cancer Center, Bellaire, TX
7Department of Leukemia, The University of Texas Health Science Center At Houston, Houston, TX
8Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

*signifies non-member of ASH